In the initiation report published on June 10, 2022, Bryan Garnier & Co initiates the coverage of the stock with a buy recommendation and values the company at 40 euros per share.

Median Technologies (ALMDT) announced today that it will be presenting an abstract at the 2022 ASCO Annual Meeting, June 3-7, McCormick Place, Chicago, IL, USA (exhibition dates: June 4-6).

With Imaging Lab, Median will provide biopharmaceutical companies with new decision-making tools for clinical trials by leveraging images with data mining and Artificial Intelligence (AI) technologies from iBiopsy® and radiomics. Imaging Lab’s solutions will support the pharmaceutical industry’s paradigm shift towards therapies targeting patients with early-stage cancers. The Imaging Lab team will be exhibiting at the ASCO Annual Conference in Chicago, June 3-7, 2022, Median’s booth #2098.

The shareholders of Median Technologies (ALMDT:PA) are invited to participate at the Shareholders’ Ordinary and Extraordinary General Meeting which will be held on Tuesday June 14, 2022, at 5:00 PM at PDGB, 174 avenue Victor Hugo – 75116 Paris.

Median has received the FDA’s feedback following the 513(g) regulatory submission for its iBiopsy® LCS CADe/CADx Software as Medical Device. Median will proceed through a 510(k) submission to obtain an FDA device clearance and market authorization, targeted for end 2023. On May 2, 2022, Median initiated a Q-submission process, composed of several submissions, to request feedback from the FDA on various topics such as the pivotal study protocols.